FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074328251> ?p ?o ?g. }

• W2074328251 endingPage "1907" @default.
• W2074328251 startingPage "1893" @default.
• W2074328251 abstract "Background: Little is known about the potential for improved adherence with and cost savings of fixed-dose combination therapy (FDCT) products compared with analogous dual therapy for type 2 diabetes mellitus. Objectives: The objectives of this study were as follows: (1) to describe patient adherence to various oral antidiabetic regimens (ie, dual therapy and FDCT); (2) to determine whether there is a difference in medication adherence between FDCT users and analogous dual-therapy users; and (3) to assess whether there is a difference in reimbursement amounts between an FDCT product and its individual components. Methods: This study was a retrospective cohort analysis using the Texas Medicaid prescription claims database. The study subjects included those who used antidiabetic FDCT or dual therapy from August 1, 2000, to July 31, 2004. The identification period of study subjects was between August 1, 2000, and July 31, 2004, including 12 months before and after the index date, so that the overall time frame was from August 1, 1999, through July 31, 2005. Prescription claims were analyzed over a 12-month preindex and 12-month postindex period. Adherence was measured using medication possession ratio (MPR), and regimen costs per tablet were assessed utilizing the index prescription. Results: Overall, 7570 FDCT users and 14,762 dual-therapy users were identified. Regarding the postindex period, FDCT users had 1.8% higher MPR compared with dual-therapy users (78.6% vs 77.2%). Patients who switched from monotherapy to FDCT had a 1.5% decrease in adherence (from 79.7% to 78.5%), whereas those who switched from monotherapy to dual therapy had a 10.0% decrease in adherence (from 83.0% to 74.7%). Those who switched from dual therapy to FDCT had a 12.4% increase in adherence (from 72.7% to 81.7%). Multivariate logistic regression analyses revealed that among preindex monotherapy users, FDCT users were significantly more likely to have higher adherence than dual-therapy users (odds ratio [OR] = 1.867; 95% CI, 1.716-2.032) after controlling for covariates, and the results were similar among preindex dual-therapy users (OR = 1.551; 95% CI, 1.204-1.999). From the perspective of the third-party payer, all FDCT products were significantly less expensive than their equivalent individual components (P < 0.001). Conclusions: Among these Texas Medicaid beneficiaries, antidiabetic FDCT users were more adherent to their regimen than dual-therapy users, and FDCT was less expensive than the analogous dual therapy. Because multiple agents are often required to achieve adequate glycemic control, it may be clinically and economically beneficial to treat eligible patients with FDCT products." @default.
• W2074328251 created "2016-06-24" @default.
• W2074328251 creator A5014971648 @default.
• W2074328251 creator A5049953443 @default.
• W2074328251 creator A5054498935 @default.
• W2074328251 creator A5061941277 @default.
• W2074328251 date "2008-10-01" @default.
• W2074328251 modified "2023-10-07" @default.
• W2074328251 title "Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients" @default.
• W2074328251 cites W119726640 @default.
• W2074328251 cites W125399422 @default.
• W2074328251 cites W1966408965 @default.
• W2074328251 cites W1971061593 @default.
• W2074328251 cites W1975588287 @default.
• W2074328251 cites W2000701945 @default.
• W2074328251 cites W2013450580 @default.
• W2074328251 cites W2018809409 @default.
• W2074328251 cites W2042353763 @default.
• W2074328251 cites W2056950322 @default.
• W2074328251 cites W2066929611 @default.
• W2074328251 cites W2070153213 @default.
• W2074328251 cites W2072852537 @default.
• W2074328251 cites W2101130434 @default.
• W2074328251 cites W2107834306 @default.
• W2074328251 cites W2114072789 @default.
• W2074328251 cites W2125914635 @default.
• W2074328251 cites W2129058494 @default.
• W2074328251 cites W2134126803 @default.
• W2074328251 cites W2136225651 @default.
• W2074328251 cites W2139062201 @default.
• W2074328251 cites W2143044822 @default.
• W2074328251 cites W2148382332 @default.
• W2074328251 cites W2160180868 @default.
• W2074328251 cites W2164733897 @default.
• W2074328251 cites W2168908161 @default.
• W2074328251 cites W2324992560 @default.
• W2074328251 cites W2786617581 @default.
• W2074328251 cites W28026197 @default.
• W2074328251 doi "https://doi.org/10.1016/j.clinthera.2008.10.003" @default.
• W2074328251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19014846" @default.
• W2074328251 hasPublicationYear "2008" @default.
• W2074328251 type Work @default.
• W2074328251 sameAs 2074328251 @default.
• W2074328251 citedByCount "75" @default.
• W2074328251 countsByYear W20743282512012 @default.
• W2074328251 countsByYear W20743282512013 @default.
• W2074328251 countsByYear W20743282512014 @default.
• W2074328251 countsByYear W20743282512015 @default.
• W2074328251 countsByYear W20743282512016 @default.
• W2074328251 countsByYear W20743282512017 @default.
• W2074328251 countsByYear W20743282512018 @default.
• W2074328251 countsByYear W20743282512019 @default.
• W2074328251 countsByYear W20743282512020 @default.
• W2074328251 countsByYear W20743282512021 @default.
• W2074328251 countsByYear W20743282512022 @default.
• W2074328251 countsByYear W20743282512023 @default.
• W2074328251 crossrefType "journal-article" @default.
• W2074328251 hasAuthorship W2074328251A5014971648 @default.
• W2074328251 hasAuthorship W2074328251A5049953443 @default.
• W2074328251 hasAuthorship W2074328251A5054498935 @default.
• W2074328251 hasAuthorship W2074328251A5061941277 @default.
• W2074328251 hasConcept C126322002 @default.
• W2074328251 hasConcept C160735492 @default.
• W2074328251 hasConcept C162324750 @default.
• W2074328251 hasConcept C167135981 @default.
• W2074328251 hasConcept C2426938 @default.
• W2074328251 hasConcept C2776534028 @default.
• W2074328251 hasConcept C2776623344 @default.
• W2074328251 hasConcept C2776999253 @default.
• W2074328251 hasConcept C2779703844 @default.
• W2074328251 hasConcept C3018553135 @default.
• W2074328251 hasConcept C50522688 @default.
• W2074328251 hasConcept C71924100 @default.
• W2074328251 hasConcept C98274493 @default.
• W2074328251 hasConceptScore W2074328251C126322002 @default.
• W2074328251 hasConceptScore W2074328251C160735492 @default.
• W2074328251 hasConceptScore W2074328251C162324750 @default.
• W2074328251 hasConceptScore W2074328251C167135981 @default.
• W2074328251 hasConceptScore W2074328251C2426938 @default.
• W2074328251 hasConceptScore W2074328251C2776534028 @default.
• W2074328251 hasConceptScore W2074328251C2776623344 @default.
• W2074328251 hasConceptScore W2074328251C2776999253 @default.
• W2074328251 hasConceptScore W2074328251C2779703844 @default.
• W2074328251 hasConceptScore W2074328251C3018553135 @default.
• W2074328251 hasConceptScore W2074328251C50522688 @default.
• W2074328251 hasConceptScore W2074328251C71924100 @default.
• W2074328251 hasConceptScore W2074328251C98274493 @default.
• W2074328251 hasIssue "10" @default.
• W2074328251 hasLocation W20743282511 @default.
• W2074328251 hasLocation W20743282512 @default.
• W2074328251 hasOpenAccess W2074328251 @default.
• W2074328251 hasPrimaryLocation W20743282511 @default.
• W2074328251 hasRelatedWork W198130337 @default.
• W2074328251 hasRelatedWork W2088113192 @default.
• W2074328251 hasRelatedWork W2103424770 @default.
• W2074328251 hasRelatedWork W2186009000 @default.
• W2074328251 hasRelatedWork W2411328445 @default.
• W2074328251 hasRelatedWork W2415225706 @default.

• next